TB Alternative Assets Ltd. Takes Position in Novo Nordisk A/S $NVO

TB Alternative Assets Ltd. purchased a new position in shares of Novo Nordisk A/S (NYSE:NVO) in the 4th quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor purchased 266,165 shares of the company’s stock, valued at approximately $13,542,000. Novo Nordisk A/S comprises 2.2% of TB Alternative Assets Ltd.’s investment portfolio, making the stock its 13th biggest holding.

Several other hedge funds have also recently modified their holdings of NVO. True Wealth Design LLC increased its stake in Novo Nordisk A/S by 209.8% in the 3rd quarter. True Wealth Design LLC now owns 443 shares of the company’s stock valued at $25,000 after buying an additional 300 shares during the period. Guerra Advisors Inc purchased a new position in Novo Nordisk A/S during the 3rd quarter worth $25,000. Strengthening Families & Communities LLC acquired a new stake in shares of Novo Nordisk A/S in the 3rd quarter worth $30,000. Allianz SE boosted its holdings in shares of Novo Nordisk A/S by 70.0% in the third quarter. Allianz SE now owns 578 shares of the company’s stock valued at $32,000 after acquiring an additional 238 shares in the last quarter. Finally, Financial Life Planners purchased a new stake in shares of Novo Nordisk A/S in the third quarter valued at about $33,000. 11.54% of the stock is owned by institutional investors and hedge funds.

Novo Nordisk A/S Trading Down 0.8%

NYSE:NVO opened at $36.44 on Thursday. Novo Nordisk A/S has a 52-week low of $35.12 and a 52-week high of $81.44. The company has a quick ratio of 0.57, a current ratio of 0.80 and a debt-to-equity ratio of 0.61. The stock has a fifty day simple moving average of $44.44 and a 200-day simple moving average of $50.07. The company has a market capitalization of $162.72 billion, a PE ratio of 10.50, a price-to-earnings-growth ratio of 8.69 and a beta of 0.73.

Novo Nordisk A/S (NYSE:NVO) last issued its quarterly earnings data on Tuesday, February 3rd. The company reported $1.01 EPS for the quarter, beating analysts’ consensus estimates of $0.90 by $0.11. Novo Nordisk A/S had a net margin of 33.03% and a return on equity of 68.91%. The firm had revenue of $12.43 billion for the quarter, compared to analysts’ expectations of $11.97 billion. On average, equities research analysts expect that Novo Nordisk A/S will post 3.84 earnings per share for the current fiscal year.

Novo Nordisk A/S Announces Dividend

The firm also recently declared a dividend, which will be paid on Wednesday, April 8th. Stockholders of record on Monday, March 30th will be given a $1.2751 dividend. The ex-dividend date is Monday, March 30th. This represents a dividend yield of 723.0%. Novo Nordisk A/S’s dividend payout ratio is currently 52.74%.

Key Novo Nordisk A/S News

Here are the key news stories impacting Novo Nordisk A/S this week:

• Positive Sentiment: Britain’s NICE recommended Wegovy to reduce heart-attack and stroke risk, which significantly expands NHS access and supports longer-term demand in a major market. British drug-cost watchdog recommends use of Novo’s Wegovy
• Positive Sentiment: Novo launched multi‑month Wegovy subscription plans and discounted pricing for self‑pay patients to improve affordability and adherence — a direct defensive response intended to protect market share and stabilize cash-pay volumes. Novo Nordisk to launch discounted Wegovy subscriptions
• Positive Sentiment: Partnerships and preferred pricing deals (e.g., with Weight Watchers and telehealth platforms) broaden distribution channels and lower effective patient costs, supporting uptake in direct‑to‑consumer channels. Weight Watchers Announces Best-in-Market Self-Pay Wegovy Pricing
• Neutral Sentiment: Novo’s U.S. head commented that category expansion from competitors can grow overall GLP‑1 demand even while intensifying competition — a mixed signal for near‑term pricing and share dynamics. Novo’s New US Chief on Lilly’s Rival Weight-Loss Pill
• Negative Sentiment: Eli Lilly’s oral obesity pill Foundayo (orforglipron) won FDA approval and is being rapidly marketed via Lilly’s direct‑to‑consumer channels — a meaningful new competitor that could pressure Novo’s pricing and market share, especially in self‑pay channels. Eli Lilly’s obesity pill approved by FDA
• Negative Sentiment: An analyst downgrade and negative commentary from market outlets point to rising concern about secular share loss and margin pressure in the face of intensifying competition and pricing moves. Seeking Alpha: Downgrade
• Negative Sentiment: Novo is cutting U.S. manufacturing jobs (about 400 roles), signaling operational adjustments amid shifting demand and pricing pressure — a near‑term cost event and a sign of market recalibration. Novo Nordisk cuts 400 jobs at Indiana manufacturing site

Analyst Ratings Changes

NVO has been the subject of several analyst reports. Zacks Research raised shares of Novo Nordisk A/S from a “strong sell” rating to a “hold” rating in a report on Tuesday, March 10th. Argus reaffirmed a “hold” rating on shares of Novo Nordisk A/S in a report on Monday, December 8th. Jefferies Financial Group upgraded Novo Nordisk A/S from an “underperform” rating to a “hold” rating in a research report on Thursday, February 12th. CICC Research initiated coverage on Novo Nordisk A/S in a research note on Friday, January 9th. They set an “outperform” rating and a $73.50 target price for the company. Finally, JPMorgan Chase & Co. reissued a “neutral” rating on shares of Novo Nordisk A/S in a report on Tuesday, February 24th. Four research analysts have rated the stock with a Buy rating, nineteen have assigned a Hold rating and one has given a Sell rating to the company’s stock. According to MarketBeat, the stock currently has a consensus rating of “Hold” and an average price target of $65.56.

Novo Nordisk A/S Company Profile

Novo Nordisk A/S is a Danish multinational pharmaceutical company headquartered in Bagsværd, Denmark, best known for its leadership in diabetes care and metabolic health. The company traces its roots to early Danish insulin production in the 1920s and was established in its current form through a 1989 merger of predecessor companies. Novo Nordisk develops, manufactures and markets pharmaceutical products and devices that address chronic and serious diseases, with a strong emphasis on long-term treatment and patient support.

The company’s core product portfolio centers on diabetes therapies, including a range of insulins and modern incretin-based treatments.